Latent Tb
Latent Tb - Related Videos
08:54
Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples
0 Views •
Cited by 5 •
2020
Current methods of analyzing patients’ adherence to complex drug resistant-tuberculosis (DR-TB) regimens can be inaccurate and resource-intensive. Our method analyzes hair, an easily collected and stored matrix, for concentrations of 11 DR-TB medications. Using LC-MS/MS, we can determine sub-nanogram drug levels that can be utilized to better understand drug adherence.
10:41
A Tuberculosis Molecular Bacterial Load Assay (TB-MBLA)
0 Views •
Cited by 18 •
2020
We describe a tuberculosis molecular bacterial load assay test performed after heat inactivation of sputum. Heat inactivation renders sputum samples noninfectious and obviates the need for containment level 3 laboratories for tuberculosis molecular tests.
07:32
Preparation of Mycobacterium tuberculosis Culture Filtrate to Understand TB Pathogenesis
0 Views •
Cited by 2 •
2025
Here, we demonstrate the preparation of Mtb culture filtrate (CF), which is the bacterial growth media that consists of proteins secreted by the bacteria. Mtb secretes proteins to modulate host signaling and immune response, which are crucial for pathogenesis. The CFs prepared are analyzed by mass spectrometry to identify all the secretory factors.
10:24
Identification of Potential Anti-TB Candidates: A Step-by-Step Guide to Synthesis, MIC Determination, and Cytotoxicity Assessment in Mammalian Cells
0 Views •
2026
Here, we present a protocol to identify potential anti-tuberculosis drug candidates through phenotypic screening, encompassing the chemical synthesis of a 4-aminoquinoline compound, determination of its minimum inhibitory concentration against Mycobacterium tuberculosis, and assessment of its cytotoxicity in mammalian cell lines.
13:22
Measurement of γHV68 Infection in Mice
0 Views •
Cited by 1 •
2011
γ-Herpesviruses (γ-HVs) establish life-long persistency in their host. Infection of mice with γ-HV68 provides a genetically tractable in vivo model for the characterization of the lifecycle/pathogenesis of γHVs. This protocol describes the detection and quantitation of γHV68 infection at acute and latent stages following infection by plaque-forming, infectious center, and qPCR assays.
FAQs
Granulomas organize immune cells around Mycobacterium tuberculosis, creating a structure that restricts bacterial growth. Macrophages and lymphocytes contribute to this containment, preventing the bacilli from multiplying freely. This immune organization helps maintain bacterial persistence without the symptoms and airborne spread associated with active tuberculosis.
Some bacilli can remain in a metabolically quiet state while immune cells limit their growth within granulomas. This persistence explains why immune control does not necessarily eliminate every bacterium. The surviving organisms can remain biologically relevant because a later weakening of immune control may permit renewed growth.
Reactivation occurs when the immune control that restricts bacterial growth weakens. Granulomas may no longer contain the persistent bacilli effectively, allowing bacterial activity to increase and disease to develop. This change matters clinically because reactivation can produce contagious tuberculosis, unlike the nontransmitting latent state.
Tuberculin skin testing and interferon-gamma release assays detect immune responses associated with infection, rather than directly describing bacterial activity. Clinical evaluation is therefore needed to exclude active disease. Interpreting test findings alongside that evaluation helps distinguish controlled infection from tuberculosis that may require assessment as active disease.
Evaluation uses either a tuberculin skin test or an interferon-gamma release assay to identify an immune response associated with Mycobacterium tuberculosis infection. Clinical evaluation then helps exclude active disease before preventive therapy is considered. This combined approach connects laboratory evidence of infection with the person’s disease status.
Preventive therapy reduces the risk that controlled infection will progress to reactivated tuberculosis. Its value follows from the biology of persistence: some bacilli can remain within granulomas even when the person has no symptoms. Treating the infection during this controlled stage supports prevention of later contagious disease and broader tuberculosis control.
Latent TB represents an important prevention stage because infection may persist before it becomes contagious disease. Identifying this state allows healthcare providers to use immune-response tests and clinical evaluation to guide preventive treatment. Reducing the chance of reactivation protects against future disease and contributes to tuberculosis control.